Lupin Ltd Receives Four Observations from U.S. FDA During Pre-Approval Inspection at Pune Biotech Facility

Lupin Ltd, a prominent pharmaceutical company, has recently undergone a product-specific Pre-Approval Inspection by the U.S. FDA at its Pune Biotech facility. The inspection, which took place from September 08 to September 19, 2025, resulted in four observations. The company has committed to addressing these observations and responding to the U.S. FDA within the specified timeframe. Lupin is dedicated to maintaining CGMP quality standards across all its facilities.